Beyond Air, Inc. (XAIR)
| Market Cap | 6.53M |
| Revenue (ttm) | 6.92M |
| Net Income (ttm) | -31.00M |
| Shares Out | 13.19M |
| EPS (ttm) | -5.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,207,325 |
| Open | 0.465 |
| Previous Close | 0.477 |
| Day's Range | 0.455 - 0.525 |
| 52-Week Range | 0.335 - 4.780 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 8.00 (+1,516.16%) |
| Earnings Date | Jun 26, 2026 |
About XAIR
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for ... [Read more]
Financial Performance
In fiscal year 2025, Beyond Air's revenue was $3.71 million, an increase of 219.67% compared to the previous year's $1.16 million. Losses were -$46.63 million, -22.60% less than in 2024.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for XAIR stock is "Buy." The 12-month stock price target is $8.0, which is an increase of 1,516.16% from the latest price.
News
Beyond Air Earnings Call Transcript: Q4 2026
Revenue more than doubled to $7.7M in fiscal 2026, driven by strong LungFit PH adoption and high renewal rates. Guidance for 2026 is $8M, with 2027 expected to reach $16–18M, assuming Gen 2 approval and launch. Gen 2 is anticipated to significantly expand the addressable market.
Beyond Air Earnings release: Q4 2026
Beyond Air released its Q4 2026 earnings on June 26, 2026, summarizing the period's financial results.
Beyond Air Annual report: Q4 2026
Beyond Air has published its Q4 2026 annual report on June 26, 2026.
Beyond Air narrows FY26 revenue view to $8M from $8M-$10M, consensus $8.08M
“We are encouraged by the market interest in the second-generation LungFit PH system, which is currently under FDA review,” continued Goodman. “Subject to FDA approval, the system is designed to…
Beyond Air sees FY27 revenue $16M-$18M, consensus $12.7M
The company said, “For calendar year 2027, the Company announced revenue guidance of $16-$18 million, representing more than 110% year-over-year growth at the midpoint compared with 2026 guidance and ...
Beyond Air reports Q4 EPS (77c) vs. ($1.79) last year
Reports Q4 revenue $1.91M, consensus $2.3M. “Fiscal 2026 was a year of meaningful transition for Beyond Air (XAIR), marked by significant progress in strengthening the foundation of our LungFit PH…
Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update
Revenue increased by 107% year-over-year to $7.7 million in the full fiscal year 2026; increased revenue by 66% YoY in the fiscal fourth quarter 2026
Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast
GARDEN CITY, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harness...
Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting
Special Meeting of Stockholders Scheduled for June 18, 2026 at 4:30 p.m. Eastern Time Proxies have been mailed to stockholders of record as of the close of business on April 20, 2026; contact informat...
Beyond Air receives Nasdaq hearing panel decision granting continued listing
Beyond Air (XAIR) announced that the Nasdaq Hearings Panel has granted the company’s request to continue its listing on The Nasdaq Stock Market, subject to regaining compliance with the exchange’s…
Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing
GARDEN CITY, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (N...
Beyond Air Proxy statement: Proxy filing
Beyond Air filed a proxy statement on May 5, 2026, providing details for shareholder voting and corporate governance matters.
Beyond Air Proxy statement: Proxy filing
Beyond Air filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Beyond Air’s Beyond Cancer reports updated data from Phase 1 UNO trial
Beyond Cancer, a subsidiary of Beyond Air (XAIR), announced updated follow-up data from its Phase 1 UNO trial, which are being presented at the American Association for Cancer Research, AACR,…
Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026
Updated AACR poster data show continued survival follow-up in heavily pre ‑ treated patients following a single intratumoral UNO injection
Beyond Air to Participate in the D. Boral Capital Global Conference 2026
GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (...
Beyond Air CEO Steve Lisi resigns, Robert Goodman succeeds
Beyond Air (XAIR) announced that Steve Lisi has resigned as CEO and stepped down from the board of directors, effective March 27 to pursue other opportunities. The board of directors…
Beyond Air subsidiary reports signs of clinical activity from UNO trial
Beyond Cancer, a subsidiary of Beyond Air (XAIR), announced early signs of clinical activity and a favorable safety and tolerability profile from its Phase 1 clinical trial evaluating a single…
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial
Data was published in the Online Itinerary Planner for the 2026 AACR Annual Meeting, and is scheduled to be presented at the meeting on April 19th Data was published in the Online Itinerary Planner fo...
Beyond Air Transcript: Life Sciences Virtual Investor Forum
Nitric oxide delivery technology is expanding globally, with FDA and CE mark approvals and a second-generation system expected to drive further growth. Quarterly revenue rose 105% year-over-year, and international expansion is underway, with new clinical data in cancer to be presented soon.
Beyond Air announces termination of NeuroNOS agreement with XTL
Beyond Air (XAIR) announced that the previously disclosed proposed transaction with XTL Biopharmaceuticals (XTLB) relating to Beyond Air’s NeuroNOS subsidiary has been terminated. The companies entere...
Beyond Air announces publication of review article on effects of iNO
Beyond Air (XAIR) commented on the publication of an independent review article providing the most comprehensive overview to date of high-dose inhaled nitric oxide, iNO, delivered at concentrations we...
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections
GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...
Beyond Air price target lowered to $2 from $6 at JonesResearch
JonesResearch lowered the firm’s price target on Beyond Air (XAIR) to $2 from $6 and keeps a Buy rating on the shares following the fiscal Q3 report. The potential commercialization…
Beyond Air Earnings Call Transcript: Q3 2026
Revenue doubled year-over-year to $2.2M, with strong hospital adoption and improved gross margin. Operating expenses and net loss declined significantly, and recent financings extend cash runway into 2027. Gen 2 LungFit PH approval is expected by end of 2026.